On December 20, 2016, the U.S. Patent and Trademark Office (USPTO) issued Patent Number PP27,475 (Cannabis Plant Named ‘Ecuadorian Sativa’) to the Company’s wholly owned subsidiary. Management believes the patented plant may prevent some cancers and may cause apoptosis of cancer cells in vivo. Attached to this filing as Exhibit 99 is a copy of a press release that more fully discusses possible medical benefits of the patented plant.

ITEM 9.01 Exhibits.

Attached to this filing as Exhibit 99 is a copy of the press release announcing the granting of Patent No. PP27,475.

PAGE

About Cannabis Sativa, Inc. (OTCMKTS:CBDS)

Cannabis Sativa, Inc. develops and promotes natural cannabis products. The Company is engaged in the research, development and licensing of natural cannabis products, including cannabis formulas, edibles, topicals, strains, recipes and delivery systems. The Company plans to develop, produce and market products through joint ventures with companies licensed under state regulations applicable to cannabis businesses. It holds the license for a medicinal cannabis strain called NZT, a cannabis lozenge delivery methodology, and a cannabis trauma cream formula. The Company is also developing a third strain of cannabis plant named CT22. The Company also conducts its operations through its subsidiary, Wild Earth Naturals, Inc. (Wild Earth). Wild Earth is an herbal skin care products formulation and marketing company that plans to target the natural healthcare products market in the United States and abroad. It offers Go Deep, Go Deep EXTRA (GDX), Face Garden, Body Garden and Lip Garden.

Cannabis Sativa, Inc. (OTCMKTS:CBDS) Recent Trading Information

Cannabis Sativa, Inc. (OTCMKTS:CBDS) closed its last trading session down -0.30 at 4.82 with shares trading hands.